Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,190,592
  • Shares Outstanding, K 258,053
  • Annual Sales, $ 9,869 M
  • Annual Income, $ 3,620 M
  • 60-Month Beta 0.40
  • Price/Sales 12.80
  • Price/Cash Flow 33.12
  • Price/Book 8.48
Trade VRTX with:

Options Overview Details

View History
  • Implied Volatility 25.15% ( +0.18%)
  • Historical Volatility 20.46%
  • IV Percentile 47%
  • IV Rank 44.96%
  • IV High 34.35% on 01/16/24
  • IV Low 17.64% on 05/16/24
  • Put/Call Vol Ratio 1.06
  • Today's Volume 1,785
  • Volume Avg (30-Day) 1,246
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 44,880
  • Open Int (30-Day) 41,905

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 3.60
  • Number of Estimates 11
  • High Estimate 4.42
  • Low Estimate 3.28
  • Prior Year 3.67
  • Growth Rate Est. (year over year) -1.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
460.69 +2.92%
on 09/11/24
500.25 -5.22%
on 08/30/24
-3.21 (-0.67%)
since 08/16/24
3-Month
458.04 +3.52%
on 08/13/24
510.64 -7.14%
on 08/01/24
+6.88 (+1.47%)
since 06/18/24
52-Week
341.85 +38.70%
on 10/03/23
510.64 -7.14%
on 08/01/24
+122.16 (+34.70%)
since 09/18/23

Most Recent Stories

More News
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

MRK : 118.64 (+0.30%)
PFE : 29.75 (-0.27%)
MRNA : 69.86 (-2.96%)
VRTX : 474.16 (-1.48%)
VKTX : 64.45 (+2.40%)
3 Stocks to Buy and Hold Forever

These stocks are built for the long run.

ABT : 114.88 (-2.75%)
ABBV : 192.94 (-0.26%)
LLY : 904.97 (-0.13%)
VRTX : 474.16 (-1.48%)
Prediction: These 3 Phenomenal Stocks Are Set to Soar

These stocks are already solid winners in 2024. They should be able to keep the momentum going.

DHI : 194.19 (-0.59%)
NVDA : 113.37 (-1.92%)
VRTX : 474.16 (-1.48%)
Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

VRTX : 474.16 (-1.48%)
$NASX : 17,573.30 (-0.31%)
BMRN : 71.14 (+0.84%)
3 No-Brainer Stocks to Buy in September

There's at least one key common denominator here: tremendous growth prospects.

LLY : 904.97 (-0.13%)
NVO : 132.06 (+0.05%)
VRTX : 474.16 (-1.48%)
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever

These three have secure core businesses, plus multiple paths to grow.

ABT : 114.88 (-2.75%)
ABBV : 192.94 (-0.26%)
VRTX : 474.16 (-1.48%)
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Vertex should have a future full of bright tomorrows.

VRTX : 474.16 (-1.48%)
Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

VRTX : 474.16 (-1.48%)
$SPX : 5,618.26 (-0.29%)
BBH : 180.65 (-0.12%)
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead

Vertex Pharmaceuticals has a lot going for it.

NVO : 132.06 (+0.05%)
VRTX : 474.16 (-1.48%)
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond

It's always a good time to invest cash in quality businesses.

VRTX : 474.16 (-1.48%)
AMZN : 186.43 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 490.74
2nd Resistance Point 487.26
1st Resistance Point 480.71
Last Price 474.16
1st Support Level 470.68
2nd Support Level 467.20
3rd Support Level 460.65

See More

52-Week High 510.64
Last Price 474.16
Fibonacci 61.8% 446.16
Fibonacci 50% 426.24
Fibonacci 38.2% 406.33
52-Week Low 341.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar